SPRYARS Pharmaceuticals, Inc.
$4.57-56% 1Y
$4.57
$4.0752 weeks$13.06
The financials
ARS Pharmaceuticals, Inc. by the numbers
ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $34M in Q2 2026 (quarter ended Jun 30, 2026), up 114% from the same quarter a year earlier. That came with net loss of $62M. For the full year FY2025, revenue was $84M (−5.5% year on year) and net income −$171M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $34M | $16M | +114% |
| Operating income | −$61M | −$48M | n/a |
| Net income | −$62M | −$45M | n/a |
| Diluted EPS | −$0.63 | −$0.46 | n/a |